Immunocore will report 2025 financial results and host a call on February 25, 2026, to provide updates.
Quiver AI Summary
Immunocore Holdings plc announced that it will report its financial results for the fourth quarter and full year of 2025 on February 25, 2026. Following the results announcement, the company will hold a live teleconference and webcast at 8:00 a.m. EST to discuss the financial outcomes and share updates on its business and portfolio. Immunocore is known for developing innovative TCR bispecific immunotherapies aimed at treating cancer, autoimmune diseases, and infectious diseases, with its leading product, KIMMTRAK, already approved for specific cancer treatments in multiple regions. The webcast can be accessed through the company's website, with a replay available afterward.
Potential Positives
- Immunocore is scheduled to report full year financial results for 2025, providing critical information to investors about the company's performance.
- The company will host a live teleconference and webcast for the results, facilitating direct communication with investors and analysts.
- Immunocore’s therapeutic KIMMTRAK has received approvals in multiple major markets, highlighting the company's successful development of its immunotherapy pipeline.
- The announcement underscores Immunocore's commitment to transparency and engagement with stakeholders through detailed updates on its business and portfolio.
Potential Negatives
- The press release focuses primarily on a future financial report, which may indicate that the company is not currently announcing positive news or developments, potentially leading to investor concern.
- The lack of immediate achievements or breakthroughs in the pipeline may suggest slow progress in critical therapeutic areas, which could impact investor confidence.
- The announcement does not include any updates on ongoing clinical trials or product pipeline advancements, leaving stakeholders without key information about the company's future prospects.
FAQ
When will Immunocore report its financial results for 2025?
Immunocore will report its financial results on February 25, 2026.
How can I access the Immunocore earnings call?
The earnings call can be accessed via the 'Events' section on Immunocore's website.
What time will Immunocore's financial results call take place?
The call is scheduled for 8:00 a.m. EST (1:00 p.m. GMT) on February 25, 2026.
What innovative therapies does Immunocore develop?
Immunocore develops TCR bispecific immunotherapies called ImmTAX to treat cancer, autoimmune, and infectious diseases.
What is Immunocore's notable therapy for uveal melanoma?
KIMMTRAK is Immunocore's approved therapy for treating unresectable or metastatic uveal melanoma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMCR Insider Trading Activity
$IMCR insiders have traded $IMCR stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $IMCR stock by insiders over the last 6 months:
- DAVID M BERMAN (HEAD OF R&D) has made 0 purchases and 13 sales selling 259,958 shares for an estimated $9,830,523.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMCR Hedge Fund Activity
We have seen 73 institutional investors add shares of $IMCR stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 989,463 shares (+357.9%) to their portfolio in Q3 2025, for an estimated $35,947,190
- WELLINGTON MANAGEMENT GROUP LLP added 567,314 shares (+13.5%) to their portfolio in Q3 2025, for an estimated $20,610,517
- BVF INC/IL added 550,000 shares (+53.7%) to their portfolio in Q3 2025, for an estimated $19,981,500
- JANUS HENDERSON GROUP PLC added 454,404 shares (+inf%) to their portfolio in Q4 2025, for an estimated $15,772,362
- CAPTION MANAGEMENT, LLC removed 369,278 shares (-79.6%) from their portfolio in Q4 2025, for an estimated $12,817,639
- BELLEVUE GROUP AG added 354,973 shares (+14.5%) to their portfolio in Q3 2025, for an estimated $12,896,169
- POINT72 ASSET MANAGEMENT, L.P. removed 284,594 shares (-34.7%) from their portfolio in Q3 2025, for an estimated $10,339,300
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMCR Analyst Ratings
Wall Street analysts have issued reports on $IMCR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 01/07/2026
- Wells Fargo issued a "Overweight" rating on 10/31/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/22/2025
To track analyst ratings and price targets for $IMCR, check out Quiver Quantitative's $IMCR forecast page.
$IMCR Price Targets
Multiple analysts have issued price targets for $IMCR recently. We have seen 4 analysts offer price targets for $IMCR in the last 6 months, with a median target of $57.5.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $100.0 on 02/04/2026
- Michael Yee from UBS set a target price of $55.0 on 01/07/2026
- Andrew Galler from Morgan Stanley set a target price of $36.0 on 11/10/2025
- Eva Fortea Verdejo from Wells Fargo set a target price of $60.0 on 10/31/2025
Full Release
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Wednesday, February 25, 2026.
Following the announcement, the Company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) to discuss its financial results and provide a business and portfolio update.
Audio Webcast
The call will be webcast live and can be accessed by visiting ‘Events’, under ‘Events and Presentations’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay will also be made available for a limited time.
Conference Call Details:
Domestic (toll-free): 877-405-1239
International (toll): +1 201-389-0851
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E:
[email protected]
Follow on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Morse
T: +1 (215) 384-4781
E:
[email protected]
